海外の治験の状況「1」での検索結果
1993件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Effect of INtervention with DMR, GLP-1 and lifestyle intensification -in Subjects with insulin dePendent type 2 diabetes- on Insulin Requirement and mEtabolic parameters
- Type 2 diabetes mellitus;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]
- Netherlands
- 2017-06-27
Authorised
- Effects of Omega-3-Fatty Acids on Arterial Endothelial Function and Intima Media Thickness in Children with Insulin-Dependent Diabetes Mellitus
- Diabetes mellitus type 1 in children
- Sweden
- 2006-09-07
Authorised
- A Phase III, Multicenter, Randomized, Double-blind, Parallel Group Study to Evaluate the Safety and Efficacy of 50 mg Oral Dosing with the Neurokinin-1 Receptor Antagonist GW679769 for the Prevention of Postoperative Nausea and Vomiting in Female Subjects at High Risk for Emesis
- Postoperative Nausea and Vomiting (PONV)
- Germany, Hungary, Ireland, United Kingdom
- 2006-02-21
Authorised
- Phase 1/2 Dose Escalation and Efficacy Study of Anti-CD38 Monoclonal Antibody in Patients with Selected CD38+ Hematological Malignancies
- Haematological malignancy MedDRA version: 20.0 Level: PT Classification code 10066476 Term: Haematological malignancy System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Brazil, Chile, Colombia, Finland, Greece, Israel, Italy, Mexico, Peru, Russian Federation, Spain, Turkey, Ukraine, United Kingdom, United States
- 2016-11-04
Authorised
- Comparison of the Safety and Efficacy of HOE901-U300 with Lantus in Children and Adolescents with Type 1 Diabetes Mellitus
- Type 1 diabetes mellitus br>MedDRA version: 19.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Argentina, Brazil, Canada, Chile, Czech Republic, France, Germany, Hungary, Israel, Italy, Japan, Latvia, Mexico, Poland, Romania, Russian Federation, Spain, United Kingdom, United States
- 2016-03-01
Authorised
- A Clinical Trial to Compare the effectiveness and safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus® (Insulin Glargine Injection) in Adults with Type 1 Diabetes Mellitus
- Type 1 diabetes mellitus br>MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Czech Republic, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine, United States
- 2017-12-13
Authorised
- A Clinical Trial to Compare the effectiveness and safety of Gan & Lee Pharmaceuticals Insulin Glargine Injection to Lantus® (Insulin Glargine Injection) in Adults with Type 1 Diabetes Mellitus
- Type 1 diabetes mellitus br>MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Czech Republic, Germany, Hungary, Poland, Russian Federation, Spain, Ukraine, United States
- 2017-11-23
Authorised
- Phase 2/3 study of rogaratinib (pan FGFR inhibitor) vs chemotherapy in patients with locally advanced or metastatic urothelial carcinoma with a high amount of specific cell growth factor receptors 1 and 3 (FGFR1 and 3) in the tumor cells
- mRNA FGF receptor 1 and 3 positive locally advanced or metastatic urothelial carcinoma progressed after prior platinum-containing chemotherapy MedDRA version: 20.0 Level: LLT Classification code 10064467 Term: Urothelial carcinoma System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Democratic People's Republic of, Netherlands, Poland, Portugal, Russian Federation, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, United Kingdom, United States
- 2018-01-18
Authorised
- Is treatment with octreotide effective in patients with head-and-neck paraganglioma? - octreotide in head and neck paraganglioma
- Patients with head-and-neck paraganglioma
- Netherlands
- 2006-05-12
Authorised
- A Randomized, Double-Blind, Placebo-controlled, Single-center Phase 1 Pilot Study to Explore the Safety and Pharmacokinetics of a Single-Dose of DAPAglifozin as Add-on to Intravenous Insulin-Infusion in Adolescent and Adult Subjects with Type 1 Diabetes mellitus
- Type 1 Diabetes mellitus;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Germany
- 2014-11-03